Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: A focus on clarithromycin

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 405-416

  Bishai, William R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extended release clarithromycin; Immunomodulatory effects; Symptom resolution

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BRONCHODILATING AGENT; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; IMMUNOMODULATING AGENT; MACROLIDE; PENICILLIN G; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TROLEANDOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIOXIDANT ACTIVITY; ASTHMA; BACTERIAL INFECTION; BIOEQUIVALENCE; CHRONIC BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; MAXILLA SINUSITIS; NAUSEA; PRIMARY MEDICAL CARE; RESPIRATORY TRACT INFECTION; REVIEW; SYMPTOMATOLOGY; TASTE DISORDER; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; CLARITHROMYCIN; HUMANS; IMMUNOLOGIC FACTORS; MAXILLARY SINUSITIS; TREATMENT OUTCOME;

EID: 33745186214     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.405     Document Type: Review

References (115)

1. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 273(3), 214-219 (1995).
2. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108(2 Suppl.), 43S-52S (1995).
3. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg. 123 (1 Pt 2), 5-31 (2000).
4. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother. 43(Suppl. A), 97-105 (1999).
5. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. 111(Suppl. 9A), 19S-24S (2001).
6. Chan J. Hadley J. The microbiology of chronic rhinosinusitis: results of a community surveillance study. Ear Nose Throat J. 80(3), 143-145 (2001).
7. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20(12), 1105-1107 (2001).
8. Swords WE, Rubin BK. Macrolide antibiotics, bacterial populations and inflammatory airway disease. Neth. J. Med. 61(7), 242-248 (2003).
9. Cervin A, Wallwork B. Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis. Orolaryngol. Clin. North Am. 38(6), 1339-1350 (2005).
10. Chinali G, Nyssen E, Di Giambattista M, Cocito C. Inhibition of polypeptide synthesis in cell-free systems by virginiamycin S and erythromycin. Evidence for a common mode of action of type B synergimycins and 14-membered macrolides. Biochim. Biophys. Acta 949(1), 71-78 (1988).
11. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125(2 Suppl.), 70S-78S (2004).
12. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr. Respir. Rev. 6(3), 227-235 (2005).
13. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am. J. Med 117(Suppl. 9A), 5S-11S (2004).
14. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125(2 Suppl.), 52S-60S (2004).
15. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125(2 Suppl.), 62S-69S (2004).
16. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 5th Edition. Elsevier Mosby, PA, USA (2005).
17. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am. J. Med. 99(6A), 26S-30S (1995).
18. Kikuchi T, Hagiwara K, Honda Y et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J. Antimicrob. Chemother 49(5), 745-755 (2002).
19. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am. J. Physiol. 272 (1 Pt 1), L15-L19 (1997).
20. Tamaoki J, Nakata J, Tagaya E, Konno K. Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas. Antimicrob. Agents Chemother. 40(7), 1726-1728 (1996).
21. Fujita K, Shimizu T, Majima Y, Sakakura Y. Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur. Arch. Otorhinolaryngol. 257(4), 199-204 (2000).
22. Kawasaki S, Koyama T, Takami K, Takizawa H, Nakamura H, Ito K. [Effects of a steroid and macrolide antibiotic on adhesion of neutrophils to the airway epithelial cells]. Jpn J. Antibiot. 51 (Suppl. A), 43-45 (1998).
23. MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv. Ther. 18(2), 75-82 (2001).
24. Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 112(10), 1827-1830 (2002).
25. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J. Exp. Med. 182(2), 115-124 (1997).
26. Ichiyama T, Nishikawa M, Yoshitomi T et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 45(1), 44-47 (2001).
27. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob. Agents Chemother. 43(11), 2678-2684 (1999).
28. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 20(6), 693-705 (1996).
29. Braga PC, Maci S, Dal Sasso M, Fonti E, Ghessi A. Effects of rokitamycin on phagocytosis and release of oxidant radicals of human polymorphonuclear leukocytes. Chemotherapy 43(3), 190-197 (1997).
30. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am. J. Respir. Crit. Care Med. 155(6), 2018-2023 (1997).
31. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 122(1), 213-218 (2002).
32. Nishi K, Mizuguchi M, Tachibana H et al. [Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome]. Nihon Kyobu Shikkan Gakkai Zasshi 33(12), 1392-1400 (1995).
33. Rhee CS, Majima Y, Arima S et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann. Otol. Rhinol. Laryngol. 109(5), 484-487 (2000).
34. Tamaoki J, Tagaya E, Sakai A, Konno K. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J. Allergy Clin. Immunol. 95(4), 853-859 (1995).
35. Takeyama K, Tamaoki J, Chiyotani A, Tagaya E, Konno K. Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in-vitro. J. Pharm. Pharmacol. 45(8), 756-758 (1993).
36. Nakano T, Ohashi Y, Tanaka A, Kakinoki Y, Washio Y, Nakai Y. Roxythromycin reinforces epithelial defence function in rabbit trachea. Acta Otolaryngol. 538, 233-238 (1998).
37. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360(9338), 978-984 (2002).
38. Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J. Cyst. Fibros. 2(2), 69-71 (2003).
39. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290(13), 1749-1756 (2003).
40. Wolter JM, Seeney SL, McCormack JG. Macrolides in cystic fibrosis: is there a role? Am. J. Respir. Med. 1(4), 235-241 (2002).
41. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol. 31(6), 464-473 (2001).
42. Anstead MI, Kuhn LH, Craigmyle L, Halsey S, Kanga JF. Effect of chronic azithromycin on lung function in cystic fibrosis. Pediatr. Pulmonol. 19, 283-284 (1999).
43. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57(3), 212-216 (2002).
44. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 13(2), 111-117 (2004).
45. Baumann U, King M, App, EM et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J. 11(2), 151-155 (2004).
46. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42(10), 773-778 (1987).
47. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology 11(3), 249-261 (2006).
48. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 157(6 Pt 1), 1829-1832 (1998).
49. Kadota J, Mukae H, Ishii H et al. Longterm efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir. Med. 97(7), 844-850 (2003).
50. Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest 107(1), 120-125 (1995).
51. Ashitani J, Mukae H, Nakazato, M et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur. Respir. J. 11(1), 104-111 (1998).
52. Ichikawa Y, Ninomiya H, Koga H et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am. Rev. Respir. Dis. 146(1), 196-203 (1992).
53. Hiratsuka T, Mukae H, Iiboshi H et al. Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 58(5), 425-430 (2003).
54. Carey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118(6), 1826-1827 (2000).
55. Rosenberg SM, Gerhard H, Grunstein MM, Schramm CM. Use of TAO without methylprednisolone in the treatment of severe asthma. Chest 100(3), 849-850 (1991).
56. Spector SL, Katz FH, Farr RS. Troleandomycin: effectiveness in steroid dependent asthma and bronchitis. J. Allergy Clin. Immunol. 54, 367-369 (1974).
57. Mestecky J, Bienenstock J. Mucosal Immunology. 3rd Edition. Elsevier Academic Press, Amsterdam, The Netherlands (2005).
58. Shimizu T, Kato M, Mochizuki H et al. Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. J. Asthma 34(3), 211-217 (1997).
59. Shimizu T, Kato M, Mochizuki H, Tokuyama K, Morikawa A, Kuroume T. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 106(2), 458-461 (1994).
60. Miyatake H, Suzuki K, Taki F, Takagi K, Satake T. Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneimittelforschung 41(5), 552-556 (1991).
61. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 99(3), 670-673 (1991).
62. Amayasu H, Yoshida S, Ebana S et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann. Allergy Asthma Immunol. 84(6), 594-598 (2000).
63. Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J. Asthma 32(3), 191-197 (1995).
64. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int. Arch. Allergy Immunol. 105(3), 308-316 (1994).
65. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 77(9), 1465-1467 (2004).
66. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I. Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant. 24(9), 1440-1443 (2005).
67. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 55(1), 10-21 (2005).
68. Chow LW, Yuen KY, Woo PC, Wei WI. Clarithromycin attenuates mastectomy-induced acute inflammatory response. Clin. Diagn. Lab. Immunol. 7(6), 925-931 (2000).
69. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3(6), 359-371 (2003).
70. Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther. 23(4), 566-577 (2001).
71. Adler JL, Jannetti W, Schneider D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin. Ther. 22(12), 1410-1420 (2000).
72. Nalepa P, Dobryniewska M, Busman T, Notario G. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr. Med. Res. Opin. 19(5), 411-420 (2003).
73. Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr. Med. Res. Opin. 21(2), 245-254 (2005).
74. Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin. Ther. 24(9), 1414-1425 (2002).
75. Murray JJ, Solomon E, McCluskey D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin. Ther. 22(12), 1421-1432 (2000).
76. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther 21(3), 576-591 (1999).
77. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 153(5), 1530-1535 (1996).
78. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary. Can. Respir. J. 10(5), 248-258 (2003).
79. Celli BR, Snider GL, Heffner J. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 152(Suppl.), 77-120 (1995).
80. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 112(6 Suppl.), 310S-313S (1997).
81. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117(5 Suppl. 2), 380S-385S (2000).
82. Mulder J, Goslings WR, Van Der Plas MC, Cardozo PL. Studies on the treatment with antibacterial drugs of acute and chronic mucopurulent bronchitis caused by Hemophilus influenzae. Acta Med. Scand. 143(1), 32-49 (1952).
83. Lees AW, Mcnaught W. Bacteriology of lqwer-respiratory-tract secretions, sputum, and upper-respiratory-tract secretions in 'normals' and chronic bronchitics. Lancet 2, 1112-1115 (1959).
84. Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin. Respir. Infect. 15(1), 59-70 (2000).
85. Fendrick AM, Saint S, Brook I, Jacobs MR, Pelton S, Sethi S. Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clin. Ther 23(10), 1683-1706 (2001).
86. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 273(12), 957-960 (1995).
87. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106(2), 196-204 (1987).
88. Wilson R, Tillotson G, Ball P. Clinical studies in chronic bronchitis: a need for better definition and classification of severity. J. Antimicrob. Chemother. 37(2), 205-208 (1996).
89. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10(Suppl. B), 3B-32B (2003).
90. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26(6), 1138-1180 (2005).
91. Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin. Ther. 23(1), 97-107 (2001).
92. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 24(4), 639-652 (2002).
93. Anzueto A, Fisher CL Jr, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther 23(1), 72-86 (2001).
94. Gwaltney JM Jr, Wiesinger BA, Patrie JT. Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history. Clin. Infect. Dis. 38(2), 227-233 (2004).
95. Carenfelt C, Melen I, Odkvist L et al. Treatment of sinus empyema in adults. A coordinated Nordic multicenter trial of cefixime vs. cefaclor. Acta Otolaryngol. 110(1-2), 128-135 (1990).
96. Carenfelt C, Eneroth CM, Lundberg C, Wretlind B. Evaluation of the antibiotic effect of treatment of maxillary sinusitis. Scand. J. Infect. Dis. 7(4), 259-264 (1975).
97. Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J. Allergy Clin. Immunol. 90(3 Pt 2), 457-461 (1992).
98. Hamory BH, Sande MA, Sydnor A Jr, Seale DL, Gwaltney JM Jr. Etiology and antimicrobial therapy of acute maxillary sinusitis. J. Infect. Dis. 139(2), 197-202 (1979).
99. Adelglass J, Jones TM, Ruoff G et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 18(6), 1255-1263 (1998).
100. Clifford K, Huck W, Shan M, Tosiello R, Echols RM, Heyd A. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. Ann. Otol. Rhinol. Laryngol. 108(4), 360-367 (1999).
101. Henry DC, Moller DJ Jr, Adelglass J et al. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. Clin. Ther. 21(2), 340-352 (1999).
102. Lasko B, Lau CY, Saint-Pierre C, Reddington JL, Martel A, Anstey RJ. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group. J. Int. Med. Res. 26(6), 281-291 (1998).
103. Dubois J, Saint-Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J. 72(12), 804-810 (1993).
104. Riffer E, Spiller J, Palmer R, Shortridge V, Busman TA, Valdes J. Once daily clarithromycin extended-release vs twice-daily amoxicillin/ clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr. Med. Res. Opin. 21(1), 61-70 (2005).
105. Corey JP, Kemker BJ, Branca JT, Kuo F, Chang Y, Gliklich RE. Health status in allergic rhinitis. Otolaryngol. Head Neck Surg. 122(5), 681-685 (2000).
106. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy 21(1), 77-83 (1991).
107. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473-483 (1992).
108. Rechtweg JS, Moinuddin R, Houser SM, Mamikoglu B, Corey JP. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope 114(5), 806-810 (2004).
109. Mitsuya Y, Kawai S, Kobayashi H. Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm. J. Infect. Chemother 6(1), 45-50 (2000).
110. Imamura Y, Yanagihara K, Mizuta Y et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob. Agents Chemother. 48(9), 3457-3461 (2004).
111. Matsui H, Eguchi M, Ohsumi K et al. Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. Antimicrob. Agents Chemother. 49(8), 3396-3403 (2005).
112. Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr. Pharm. Des. 10(25), 3055-3065 (2004).
113. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 34(5), 863-870 (1990).
114. Nadel JA, Takeyama K, Agusti C. Role of neutrophil elastase in hypersecretion in asthma. Eur. Respir. J. 13(1), 190-196 (1999).
115. Takahashi Y, Shimizu T, Sakakura Y. Effects of indomethacin, dexamethasone, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium. Ann. Otol. Rhinol. Laryngol. 106(8), 683-687 (1997).